AstraZeneca shares rose 5.2% after better-than-expected Q3 results and unchanged full-year guidance. Bank of America analysts say investors are now debating the 2027 profitability outlook, expecting mid-to-high single-digit sales growth and low double-digit core EPS growth. The company faces a busy 2027 with clinical-trial catalysts needed to address pipeline setback concerns.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
